USD
$0.00
(0.00%
)At Close (As of Oct 15, 2025)
$214.06B
Market Cap
13.21
P/E Ratio
6.41
EPS
$106.25
52 Week High
$71.87
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $49B |
Total Revenue | $64B |
Cost Of Revenue | $15B |
Costof Goods And Services Sold | $15B |
Operating Income | $20B |
Selling General And Administrative | $7.7B |
Research And Development | $18B |
Operating Expenses | $29B |
Investment Income Net | - |
Net Interest Income | -$856M |
Interest Income | $415M |
Interest Expense | $1.3B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $4.5B |
Income Before Tax | $20B |
Income Tax Expense | $2.8B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $17B |
Comprehensive Income Net Of Tax | - |
Ebit | $21B |
Ebitda | $26B |
Net Income | $17B |
Field | Value (USD) |
---|---|
Total Assets | $117B |
Total Current Assets | $39B |
Cash And Cash Equivalents At Carrying Value | $13B |
Cash And Short Term Investments | $13B |
Inventory | $6.1B |
Current Net Receivables | $10B |
Total Non Current Assets | $78B |
Property Plant Equipment | $25B |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $16B |
Intangible Assets Excluding Goodwill | $16B |
Goodwill | $22B |
Investments | - |
Long Term Investments | $463M |
Short Term Investments | $447M |
Other Current Assets | $8.7B |
Other Non Current Assets | - |
Total Liabilities | $71B |
Total Current Liabilities | $28B |
Current Accounts Payable | $4.1B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.9B |
Total Non Current Liabilities | $42B |
Capital Lease Obligations | - |
Long Term Debt | $34B |
Current Long Term Debt | $2.6B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $38B |
Other Current Liabilities | $17B |
Other Non Current Liabilities | $6.5B |
Total Shareholder Equity | $46B |
Treasury Stock | - |
Retained Earnings | $63B |
Common Stock | $1.8B |
Common Stock Shares Outstanding | $2.5B |
Field | Value (USD) |
---|---|
Operating Cashflow | $21B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $4.5B |
Capital Expenditures | $3.4B |
Change In Receivables | - |
Change In Inventory | -$835M |
Profit Loss | - |
Cashflow From Investment | -$7.7B |
Cashflow From Financing | -$7B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $7.8B |
Dividend Payout Common Stock | $7.8B |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$1.3B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $17B |
Field | Value (USD) |
---|---|
Gross Profit | $49B |
Total Revenue | $64B |
Cost Of Revenue | $15B |
Costof Goods And Services Sold | $15B |
Operating Income | $20B |
Selling General And Administrative | $7.7B |
Research And Development | $18B |
Operating Expenses | $29B |
Investment Income Net | - |
Net Interest Income | -$856M |
Interest Income | $415M |
Interest Expense | $1.3B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $4.5B |
Income Before Tax | $20B |
Income Tax Expense | $2.8B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $17B |
Comprehensive Income Net Of Tax | - |
Ebit | $21B |
Ebitda | $26B |
Net Income | $17B |
Field | Value |
---|---|
Ex Dividend Date | 2025-09-15 |
Declaration Date | 2025-07-22 |
Record Date | 2025-09-15 |
Payment Date | 2025-10-07 |
Amount | 0.81 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Merck & Company Inc. is a prominent American multinational pharmaceutical corporation headquartered in Kenilworth, New Jersey, celebrated for its dedication to enhancing global health through cutting-edge pharmaceuticals and vaccines. Established in 1891 as the U.S. subsidiary of the German Merck Group, Merck has a rich history of scientific innovation, focusing on critical therapeutic areas such as oncology, infectious diseases, and cardiovascular health. The company boasts a robust pipeline of novel therapies and a strong commitment to research and development, positioning itself as a leader in the biopharmaceutical sector. By prioritizing patient outcomes and healthcare accessibility, Merck is well-equipped to navigate the evolving healthcare landscape, driving both growth and innovation through its scientific prowess and strategic collaborations.